Physicians' Academy for Cardiovascular Education

ACS

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

Hypertension stage 1 at early 40s in women associated with increased ACS risk during midlife

Literature - June 22, 2021 - Kringeland E, et al. - Eur J Prev Cardiol 2021
Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.

Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD
Prof. Chew summarizes the 12-months follow-up findings of the rapid TnT trial comparing two protocols of hs-troponin in patients with suspected ACS. He also gives his interpretation of the results.

ACC 2021 Prof. Chew summarizes the 12-months follow-up findings of the rapid TnT trial comparing two protocols of hs-troponin in patients with suspected ACS. He also gives his interpretation of the results.

Concurrent use of DOAC and aspirin without indication associated with increased bleeding in AF and VTE

Literature - May 5, 2021 - Schaefer JK et al. - JAMA Intern Med. 2021

This registry-based cohort study showed that one-third of patients with AF and/or VTE on a DOAC received aspirin without clear therapeutic indication. Combination therapy was associated with increased bleeding rates compared to DOAC monotherapy.

Inverse association between plasma long-chain omega-3-PUFAs content and sudden cardiac death after ACS

Literature - Apr. 21, 2021 - Zelniker TA, et al. - J Am Heart Assoc 2021

A higher relative proportion of plasma long-chain omega-3 polyunsaturated fatty acids (PUFAs) was associated with lower risk of sudden cardiac death in patients after ACS.

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD
As author of a Clinical Review in European Heart Journal, Niels van der Sangen discusses the options for a personalized approach of antithrombotic therapy after PCI, as described in the paper.

As an author of a Clinical Review in European Heart Journal, Niels van der Sangen discusses the options for a personalized approach of antithrombotic therapy after PCI, as described in the paper.

Similar risk reductions in MACE with achieved LDL-c <25 mg/dL and 25-50 mg/dL with PCSK9i

Literature - Feb. 18, 2021 - Schwartz GG, et al. - Circulation. 2021

This subanalysis of the ODYSSEY OUTCOMES trial showed that patients with recent ACS on alirocumab with achieved LDL-c <25 mg/dL had similar risk reductions for MACE as patients with LDL-c 25-50 mg/dL.

Similar risk of NACE when comparing two P2Y12 inhibitors in patients with ACS after PCI

Literature - Dec. 15, 2020 - You SC, et al. - JAMA. 2020

In a retrospective study, ticagrelor treatment resulted in comparable risk of net adverse clinical events (NACE) compared to clopidogrel treatment among patients from the US and South-Korea with ACS who underwent PCI.

Comparison of two P2Y12 inhibitors in ACS patients with diabetes

Literature - Nov. 9, 2020 - Ndrepepa G, et al. - JACC Cardiovasc Interv 2020

A prespecified subanalysis of ISAR-REACT 5 demonstrated that ticagrelor and prasugrel had comparable efficacy with regard to reducing ischemic events in patients with diabetes, with a similar risk for bleeding.

Total CV events lowered by PCSK9i-induced Lp(a) reduction in ACS patients

Literature - Nov. 6, 2020 - Szarek M, et al. - Eur Heart J. 2020

A post-hoc analysis of the ODYSSEY OUTCOMES trial found that Lp(a) reduction with alirocumab was, independent of LDL-c reduction, associated with reduced total CV events in ACS patients.

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD
Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Prof. Mach explains the recommendations for pharmacological LDL-c lowering as described in the 2019 ESC/EAS guidelines for the management of dyslipidemia.

Malnutrition in ACS patients associated with increased risk of mortality and MACE

Literature - Aug. 26, 2020 - Raposeiras Roubín S, et al. - J Am Coll Cardiol 2020

Malnutrition, assessed by 3 different scores, was common in a cohort of ACS patients. Malnutrition was associated with increased risk of mortality and MACE, independent of BMI.

PCSK9i initiated within 24 hours of ACS presentation rapidly lowers LDL-c

Literature - Aug. 24, 2020 - Leucker TM et al., - Circulation. 2020 Jul 28;142(4):419-421.

This trial in 57 patients with non-STEMI and troponin I ≥5 ng/mL showed that more patients reach LDL-c targets at hospital discharge with evolocumab plus high-intensity statin therapy compared with placebo plus high-intensity statin therapy.